CENTRE GEORGES FRANCOIS LECLERC

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.

Not Applicable

Not yet recruiting

Conditions: All Types of Metastatic Solid Malignancy
1st-line Treatment
Exome Analysis
Active File EXOMA2 Study

Interventions: Other: Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 80

Registration Number: NCT06550687

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷
CHU François Mitterand, Dijon, France

Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.

Not Applicable

Not yet recruiting

Conditions: Patients With Metastatic Castration-resistant Prostate Cancer

Interventions: Radiation: 177Lu-PSMA-617 PET scan

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-18

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 35

Registration Number: NCT06136377

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners

Not yet recruiting

Conditions: Breast Cancer

Interventions: Other: Questionnaires
Other: Communication of the results of the BRCA1/2 ultra rapid test

First Posted Date: 2023-11-01

Last Posted Date: 2024-02-12

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 150

Registration Number: NCT06111417

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: FOLFIRINOX treatment

First Posted Date: 2023-08-14

Last Posted Date: 2024-02-12

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 90

Registration Number: NCT05988814

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, France

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Phase 1

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Phase I - Mirdametinib - Level 1
Drug: Phase I - Mirdametinib - Level 4
Drug: Phase II - Mirdametinib
Drug: Phase I - Mirdametinib - Level 2
Drug: Phase I - Mirdametinib - Level 3

First Posted Date: 2023-07-10

Last Posted Date: 2024-02-13

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 24

Registration Number: NCT05937906

Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions

Not Applicable

Recruiting

Conditions: Patient With Radiotherapy (Linac MRI)
Mobile Cancerous Lesion

Interventions: Combination Product: With non-magnetic screen

First Posted Date: 2023-03-24

Last Posted Date: 2023-10-17

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 100

Registration Number: NCT05783908

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, Côte d'Or, France

Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Other: Placebo
Drug: OnLife®

First Posted Date: 2023-01-25

Last Posted Date: 2024-04-22

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 60

Registration Number: NCT05695313

Locations: 🇫🇷
Centre Georges François Leclerc, Dijon, France

Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV

Not Applicable

Recruiting

Conditions: Non-small Cell Bronchopulmonary Carcinoma at Stage IV and Benefiting From First-line Treatment According to Current French Recommendations

Interventions: Other: Test Leeds Food Preference Questionnaire (LFQP-France)

First Posted Date: 2022-08-11

Last Posted Date: 2024-02-12

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 190

Registration Number: NCT05496556

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, Côte d'Or, France

Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration

Not Applicable

Recruiting

Conditions: Localized Breast Cancer

Interventions: Drug: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
Drug: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)

First Posted Date: 2022-03-25

Last Posted Date: 2024-02-29

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 100

Registration Number: NCT05296317

Locations: 🇫🇷
Centre Georges François Leclerc (CGFL), Dijon, Bourgogne, France

Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer.

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: Surgery for unilateral breast reconstruction

First Posted Date: 2022-03-14

Last Posted Date: 2023-10-17

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 32

Registration Number: NCT05278741

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, Côte d'Or, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy